Bioventus shares are trading higher after Craig-Hallum maintained a Buy rating on the stock and raised its price target from $12 to $17.
Portfolio Pulse from Benzinga Newsdesk
Bioventus shares rise as Craig-Hallum maintains a Buy rating and increases the price target from $12 to $17.
September 27, 2024 | 3:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bioventus shares are trading higher following Craig-Hallum's decision to maintain a Buy rating and increase the price target from $12 to $17.
The increase in price target from $12 to $17 by Craig-Hallum, along with the maintained Buy rating, is a positive signal to investors, likely leading to increased buying interest and a rise in Bioventus's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100